公开(公告)号：US20120136322A1

公开(公告)日：2012-05-31

申请号：US13151001

申请日：2011-06-01

Applicant: Yair Alster ,  Eugene de Juan, JR. ,  Cary J. Reich ,  Stephen Boyd ,  David Sierra ,  Jose D. Alejandro ,  K. Angela Macfarlane ,  Douglas Sutton

Inventor： Yair Alster ,  Eugene de Juan, JR. ,  Cary J. Reich ,  Stephen Boyd ,  David Sierra ,  Jose D. Alejandro ,  K. Angela Macfarlane ,  Douglas Sutton

IPC: A61F9/00 ,  A61M35/00

CPC classification number: A61F9/0026 ,  A61F9/0017 ,  A61K9/0051 ,  A61K31/19 ,  A61K31/335 ,  A61K31/407 ,  A61K31/4178 ,  A61K31/43 ,  A61K31/5377 ,  A61K31/5415 ,  A61K31/55 ,  A61K31/557 ,  A61K31/5575 ,  A61K31/56 ,  A61K31/568 ,  A61K31/573 ,  A61K31/58 ,  A61K31/7036 ,  A61K38/00 ,  A61M31/002

Abstract: A therapeutic system comprises an ocular insert placed on a region outside an optical zone of an eye. The ocular insert comprises two structures: a first skeletal structure and a second cushioning structure. The first structure functions as a skeletal frame which maintains positioning of the implant along the anterior portion of the eye and provides support to the second, cushioning structure. This first structure maintains the attachment of the therapeutic system to the anterior portion of the eye for at least thirty days. In some embodiments the first structure remains a constant size and shape, e.g. a ring shape, a ring with haptics, or a curvilinear ring that is confined to and restrainingly engages the inferior and superior conjunctival fornices so as to retain the implant within the tear fluid and/or against the tissues of the eye.

Abstract translation: 治疗系统包括放置在眼睛的光学区域外的区域上的眼部插入物。 眼睛插入件包括两个结构：第一骨架结构和第二缓冲结构。 第一结构用作骨架框架，其保持沿着眼睛前部的植入物的定位，并向第二缓冲结构提供支撑。 该第一结构将治疗系统的附着维持在眼前部至少三十天。 在一些实施例中，第一结构保持恒定的尺寸和形状，例如。 环形，具有触觉的环或曲线环，其限制并限制性地接合下部和上结膜，以将植入物保持在泪液和/或针对眼睛的组织。

公开(公告)号：US08172899B2

公开(公告)日：2012-05-08

申请号：US13245772

申请日：2011-09-26

Applicant: Thomas A. Silvestrini ,  Eugene de Juan, Jr.

Inventor： Thomas A. Silvestrini ,  Eugene de Juan, Jr.

IPC: A61F2/14

CPC classification number: A61F9/00781 ,  A61F2210/0019

Abstract: Described herein are devices and methods for treating eye conditions. Described is an ocular implant including an elongate member having an internal lumen forming a flow pathway, at least one inflow port communicating with the flow pathway, and at least one outflow port communicating with the flow pathway. The elongate member is adapted to be positioned in the eye such that at least one inflow port communicates with the anterior chamber, at least one outflow port communicates with the suprachoroidal space to provide a fluid pathway between the anterior chamber and the suprachoroidal space when the elongate member is implanted in the eye. The elongate member has a wall material imparting a stiffness to the elongate member. The stiffness is selected such that after implantation the elongate member deforms eye tissue surrounding the suprachoroidal space forming a tented volume.

公开(公告)号：US20110087148A1

公开(公告)日：2011-04-14

申请号：US12970567

申请日：2010-12-16

Applicant: Thomas A. Silvestrini ,  Eugene de Juan, JR.

Inventor： Thomas A. Silvestrini ,  Eugene de Juan, JR.

IPC: A61F9/00

CPC classification number: A61F9/00781 ,  A61F2210/0019

Abstract: Described herein are devices and methods for treating eye conditions. Described is an ocular implant including an elongate member having an internal lumen forming a flow pathway, at least one inflow port communicating with the flow pathway, and at least one outflow port communicating with the flow pathway. The elongate member is adapted to be positioned in the eye such that at least one inflow port communicates with the anterior chamber, at least one outflow port communicates with the suprachoroidal space to provide a fluid pathway between the anterior chamber and the suprachoroidal space when the elongate member is implanted in the eye. The elongate member has a wall material imparting a stiffness to the elongate member. The stiffness is selected such that after implantation the elongate member deforms eye tissue surrounding the suprachoroidal space forming a tented volume.

Abstract translation: 本文描述了用于治疗眼睛状况的装置和方法。 描述了一种眼部植入物，其包括具有形成流动路径的内部内腔的细长构件，与流动通道连通的至少一个流入口以及与流动通路连通的至少一个流出口。 细长构件适于定位在眼睛中，使得至少一个流入端口与前房连通，至少一个流出端口与脉管外空间连通，以在前房和脉管外空间之间提供流体通路，当细长 成员植入眼睛。 细长构件具有赋予细长构件刚性的壁材料。 选择刚度使得在植入之后，细长构件使围绕脉管外空间的眼组织变形，形成帐篷体积。

公开(公告)号：US20100255061A1

公开(公告)日：2010-10-07

申请号：US12696678

申请日：2010-01-29

Applicant: Eugene de Juan, JR. ,  Yair Alster ,  Steven M. Chamow ,  Kathleen Cogan Farinas ,  Hanson S. Gifford, III ,  K. Angela MacFarlane ,  Cary J. Reich ,  Michael Barrett ,  Randolph E. Campbell ,  Robert George ,  Douglas Sutton

Inventor： Eugene de Juan, JR. ,  Yair Alster ,  Steven M. Chamow ,  Kathleen Cogan Farinas ,  Hanson S. Gifford, III ,  K. Angela MacFarlane ,  Cary J. Reich ,  Michael Barrett ,  Randolph E. Campbell ,  Robert George ,  Douglas Sutton

IPC: A61F9/00 ,  A61K39/395 ,  A61P27/02 ,  A61K31/5575 ,  A61K31/58 ,  A61F2/14 ,  B23P17/04

CPC classification number: G01N33/558 ,  A61F9/0017 ,  A61K9/0048 ,  A61K9/0051 ,  A61K31/57 ,  A61K31/573 ,  A61K31/58 ,  A61K38/385 ,  A61K47/32 ,  A61K47/34 ,  A61K47/38 ,  A61K2039/505 ,  C07K16/22 ,  C07K2317/24 ,  C07K2317/55 ,  Y10T29/49826

Abstract: A therapeutic device to release a therapeutic agent comprises a porous structure coupled to a container comprising a reservoir. The reservoir comprises a volume sized to release therapeutic amounts of the therapeutic agent for an extended time when coupled to the porous structure and implanted in the patient. The porous structure may comprise a first side coupled to the reservoir and a second side to couple to the patient to release the therapeutic agent. A plurality of interconnecting channels can extend from the first side to the second side so as to connect a first a plurality of openings on the first side with a second plurality of openings on the second side. Each of the openings on the first side can be connected to each of the openings on the second side with the plurality of interconnecting channels, such that the rate of release of the therapeutic agent can be substantially maintained when one or more of the openings is blocked, for example with particles, cells, bacteria or tissue when the device is implanted for an extended time. The length of the channels extending from the first side to the second side may comprise an effective length greater than a distance across the porous structure from the first side to the second side. The therapeutic device many comprise an expandable retention structure and an expandable reservoir, such that the device can be delivered from a lumen of a delivery device and expand when positioned in the patient. The therapeutic device may comprises a penetrable barrier to inject therapeutic agent into the device when implanted in the patient.

Abstract translation: 用于释放治疗剂的治疗装置包括联接到包括储存器的容器的多孔结构。 储存器包括体积大小，当耦合到多孔结构并且植入患者体内时，释放治疗剂量的治疗剂延长的时间。 所述多孔结构可以包括联接到所述储存器的第一侧和与所述患者联接以释放所述治疗剂的第二侧。 多个互连通道可以从第一侧延伸到第二侧，以便将第一侧上的第一多个开口与第二侧上的第二多个开口连接。 第一侧的每个开口可以与多个互连通道连接到第二侧的每个开口，使得当一个或多个开口被阻塞时可以基本上保持治疗剂的释放速度 ，例如当器件长时间植入时，可以使用颗粒，细胞，细菌或组织。 从第一侧延伸到第二侧的通道的长度可以包括大于多孔结构从第一侧到第二侧的距离的有效长度。 治疗装置许多包括可扩张的保留结构和可扩张的储存器，使得该装置可以从输送装置的内腔输送，并且在定位在患者体内时膨胀。 治疗装置可以包括当植入患者时将治疗剂注入装置中的可穿透屏障。

公开(公告)号：US20090092654A1

公开(公告)日：2009-04-09

申请号：US12332219

申请日：2008-12-10

Applicant: Eugene de Juan, JR. ,  Cary Reich ,  Stephen Boyd ,  Hanson G. Gifford, III ,  Mark Deem

Inventor： Eugene de Juan, JR. ,  Cary Reich ,  Stephen Boyd ,  Hanson G. Gifford, III ,  Mark Deem

IPC: A61L27/54 ,  A61L27/58 ,  A61K38/13 ,  A61K31/5377 ,  A61K31/215 ,  A61K31/165 ,  A61P27/02 ,  A61P27/06

CPC classification number: A61K9/0051 ,  A61F9/0017 ,  A61F9/0026 ,  A61F9/00772 ,  A61F9/00781 ,  A61F2220/0008 ,  A61F2250/0067 ,  A61F2250/0087 ,  A61K9/00 ,  A61K9/0017 ,  A61K9/06 ,  A61K31/215 ,  A61K31/216 ,  A61K31/55 ,  A61K31/557 ,  A61K31/5575 ,  A61K31/573 ,  A61K47/34 ,  A61L31/16

Abstract: An implant for insertion into a punctum of a patient comprises a body. The body has a distal end, a proximal end, and an axis therebetween. The distal end of the body is insertable distally through the punctum into the canalicular lumen. The body comprises a therapeutic agent included within an agent matrix drug core. Exposure of the agent matrix to the tear fluid effects an effective therapeutic agent release into the tear fluid over a sustained period. The body has a sheath disposed over the agent matrix to inhibit release of the agent away from the proximal end. The body also has an outer surface configured to engage luminal wall tissues so as to inhibit expulsion when disposed therein. In specific embodiments, the agent matrix comprises a non-bioabsorbable polymer, for example silicone in a non-homogenous mixture with the agent.

Abstract translation: 用于插入患者的泪点的植入物包括主体。 主体具有远端，近端和它们之间的轴线。 身体的远端可以通过泪点向远端插入到小管腔内。 身体包含药剂基质药物核心内的治疗剂。 试剂基质暴露于泪液能够在持续的时间内有效的治疗剂释放到泪液中。 身体具有设置在药剂基质上的护套以抑制药剂远离近端的释放。 身体还具有被配置为接合腔壁组织的外表面，以便当设置在其中时阻止排出。 在具体实施方案中，试剂基质包含非生物可吸收聚合物，例如与该试剂的非均匀混合物的硅氧烷。

公开(公告)号：US06969384B2

公开(公告)日：2005-11-29

申请号：US09756649

申请日：2001-01-03

Applicant: Eugene de Juan, Jr. ,  Patrick S. Jensen

Inventor： Eugene de Juan, Jr. ,  Patrick S. Jensen

IPC: A61B8/10 ,  A61B8/12 ,  A61B17/00 ,  A61B17/28 ,  A61B19/00 ,  A61F9/00 ,  A61F9/007 ,  A61M25/00

CPC classification number: A61B5/6848 ,  A61B5/6885 ,  A61B8/10 ,  A61B8/12 ,  A61B8/4461 ,  A61B8/4488 ,  A61B17/00234 ,  A61B17/29 ,  A61B34/76 ,  A61B2017/00022 ,  A61B2017/00115 ,  A61B2017/00128 ,  A61B2017/00345 ,  A61B2017/00477 ,  A61B2017/00734 ,  A61B2090/0813 ,  A61F9/0017 ,  A61F9/007 ,  A61M25/00

Abstract: Featured are surgical devices that provide enhanced perceptual feedback to a medical practitioner in the form of e.g. tactile sensations or auditory feedback, and methods of use of the devices. The devices and methods of the present invention are particularly suitable for microsurgery applications including ophthalmic or neurosurgical procedures. Use of the present devices and methods will enhance user feedback, allowing for improved perception, thereby increasing performance, speed, and accuracy of surgical procedures.

Abstract translation: 特色是提供增强的感知反馈给外科医生的手术装置，其形式为例如 触觉或听觉反馈，以及设备的使用方法。 本发明的装置和方法特别适用于显微外科应用，包括眼科或神经外科手术。 使用本设备和方法将增强用户的反馈，允许改进的感知，从而提高外科手术的性能，速度和准确性。

公开(公告)号：US06572608B1

公开(公告)日：2003-06-03

申请号：US09545143

申请日：2000-04-07

Applicant: Eric T. Lee ,  Patrick S. Jensen ,  Anthony D. Cornetto, III ,  Terry H. Shelley ,  Carl C. Awh ,  Eugene de Juan, Jr. ,  Michael D. Auld ,  Gregg D. Scheller

Inventor： Eric T. Lee ,  Patrick S. Jensen ,  Anthony D. Cornetto, III ,  Terry H. Shelley ,  Carl C. Awh ,  Eugene de Juan, Jr. ,  Michael D. Auld ,  Gregg D. Scheller

IPC: A61B1818

CPC classification number: A61F9/008 ,  A61B2017/00331 ,  A61B2017/00867 ,  A61B2018/2238 ,  A61B2018/2288 ,  A61F2009/00863

Abstract: A microsurgical laser probe is provided with a distal end portion of an optic fiber that projects from a tubular sleeve of the probe and can be caused to bend relative to the probe sleeve by manual manipulation of a mechanism on a handle of the probe.

公开(公告)号：US06399655B1

公开(公告)日：2002-06-04

申请号：US09218956

申请日：1998-12-22

Applicant: Eugene de Juan, Jr.

Inventor： Eugene de Juan, Jr.

IPC: A61K3135

CPC classification number: A61K31/35 ,  A61K31/352 ,  A61K31/52 ,  A61K45/06 ,  Y10S514/912 ,  A61K31/015 ,  A61K31/05 ,  A61K2300/00

Abstract: The present invention is directed to a method for the prophylactic treatment of cataract. The method involves the administration of a compound of Formula I wherein V, W and X are selected from the group consisting of hydro, hydroxyl, alkoxy, halo, an ester, an ether, a carboxylic acid group, a pharmaceutically acceptable salt of a carboxylic acid group, and —SR, in which R is hydrogen or an alkyl group, Y is selected from the group consisting of oxygen, sulfur, C(OH), and C═O, and Z is selected from the group consisting of hydro and C(O)OR1, wherein R1 is an alkyl, or an analogue or prodrug thereof or a pharmaceutically acceptable salt of any of the foregoing to an animal, such as a mammal, in particular a human, in an amount sufficient to treat cataracts prophylactically. The compound of Formula I is preferably genistein.

Abstract translation: 本发明涉及一种预防白内障治疗的方法。 该方法包括施用式I化合物，其中V，W和X选自氢，羟基，烷氧基，卤素，酯，醚，羧酸基，羧酸的药学上可接受的盐 基团和-SR，其中R是氢或烷基，Y选自氧，硫，C（OH）和C = O，Z选自氢和C （O）OR1，其中R 1是烷基，或其类似物或前药，或任何前述物质的药学上可接受的盐，其量足以预防性治疗白内障的动物，例如哺乳动物，特别是人。 式I的化合物优选是染料木素。

公开(公告)号：US6028099A

公开(公告)日：2000-02-22

申请号：US41601

申请日：1998-03-13

Applicant: Eugene de Juan, Jr.

Inventor： Eugene de Juan, Jr.

IPC: A67K31/35 ,  A67K31/389

CPC classification number: A61K31/352 ,  A61K31/382 ,  Y10S514/912

Abstract: The present invention is directed to a method for the prophylactic and therapeutic treatment of choroidal neovascularization. The method involves the administration of an inhibitor of the protein tyrosine kinase pathway to an animal, such as a mammal, in particular a human, in an amount sufficient to treat the choroid for neovascularization prophylactically or therapeutically. The inhibitor of the protein tyrosine kinase pathway is preferably genistein or an analogue or prodrug thereof or a pharmaceutically acceptable salt of any of the foregoing.

Abstract translation: 本发明涉及脉络膜新血管形成的预防和治疗方法。 该方法包括将蛋白酪氨酸激酶途径的抑制剂施用于动物，例如哺乳动物，特别是人，其量足以预防或治疗地治疗脉络膜用于新生血管形成。 蛋白酪氨酸激酶途径的抑制剂优选为染料木素或其类似物或前药，或上述任一项的药学上可接受的盐。

公开(公告)号：US5944747A

公开(公告)日：1999-08-31

申请号：US041932

申请日：1998-03-13

Applicant: Robert J. Greenberg ,  Mark S. Humayun ,  Eugene de Juan, Jr.

Inventor： Robert J. Greenberg ,  Mark S. Humayun ,  Eugene de Juan, Jr.

IPC: A61F9/08 ,  A61N1/36 ,  A61N1/32

CPC classification number: A61N1/36046

Abstract: A method of focused phosphene generation through deeper intermediate retinal cellular electrical stimulation to the exclusion of direct ganglion cellular electrical stimulation comprises the steps of: a) positioning a stimulating electrode in the vicinity of retinal tissue; and b) applying a long duration stimulation signal to the electrode such that deeper intermediate retinal cells are preferentially stimulated over the retinal ganglion cells and proximal overlying surface axons. The long duration stimulation signal is preferably a biphasic signal having a negative and a positive phase pulse which is applied in cathodic fashion. To preferentially stimulate the deeper intermediate retinal elements the duration of the long duration stimulation signal is greater than 0.5 millisecond per phase pulse, and preferably equal to or longer than 2 millisecond per phase pulse. The biphasic signal is preferably adjusted to simulate a monophasic signal by adjusting the magnitude of the negative pulse in relation to positive pulse, and by adjusting the duration of the positive pulse in relation to the negative pulse to maintain approximately net zero charge introduction. Preferably, the ratio of the negative pulse to the positive pulse is approximately 10:1 or greater.

Abstract translation: 通过更深的中间视网膜细胞电刺激产生聚焦磷酸的方法排除直接神经节细胞电刺激包括以下步骤：a）将刺激电极定位在视网膜组织附近; 和b）对电极施加长时间刺激信号，使得较深的中间视网膜细胞优先在视网膜神经节细胞和近侧上表面轴突上被刺激。 长持续时间刺激信号优选是具有以阴极方式施加的负相和正相脉冲的双相信号。 为了优先地刺激较深的中间视网膜元件，长时间刺激信号的持续时间大于每相脉冲0.5毫秒，并且优选地等于或大于每相脉冲2毫秒。 优选地调节双相信号以通过相对于正脉冲调整负脉冲的幅度，并通过相对于负脉冲调整正脉冲的持续时间来维持近似净零电荷引入来模拟单相信号。 优选地，负脉冲与正脉冲的比率为大约10:1或更大。